Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: Correlation with virologic response and survival

Journal of Medical Virology

Volumn 49, Issue 4, 1996, Pages 303-310

  Shepp, David H ^a,b   Ashraf, Amar ^a,c   Tang, Ian T L ^a,d   Match, Mark E ^a   Millan, Colleen ^b   Pergolizzi, Robert ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

AIDS; AZT; ddl; Resistance; Zidovudine

Indexed keywords

DIDANOSINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; SURVIVAL;

ANTI-HIV AGENTS; DIDANOSINE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; RETROVIRIDAE PROTEINS; RNA-DIRECTED DNA POLYMERASE; SURVIVAL;

EID: 0029776358     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199608)49:4<303::AID-JMV8>3.0.CO;2-7     Document Type: Article

References (34)

1. Boucher CAB, van Leeuwen R, Kellam P, Schipper P, Tijnagel J, Lange MJA, Larder BA, (1993): Effects of discontinuation of zidovudine treatment of zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrobial Agents and Chemotherapy 37:1525-1530.
2. CDC (1992): 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41(RR-17):1-19.
3. Demeter LM, Nawaz T, Morse G, Dolin R, Dexter A, Gerondelis P, Reichman RC (1995): Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. Journal of Infectious Diseases 172:1480-1485.
4. Gazzard B (1996): Further results from European/Australia Delta Trial. 3rd Conference on Retroviruses and Opportunistic Infections. Washington D.C. (abstract LB5a).
5. Gao Q, Gu Z, Parniak MA, Li X, Wainberg MA (1992): In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′-3′-dideoxyinosine. Journal of Virology 66:12-19.
6. Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA (1992): Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. Journal of Virology 66:7128-7135.
7. Gu Z, Gao Q, Fang, H, Salomon H, Parniak MA, Goldberg E, Cameron J, Wainberg MA (1994): Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′-,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents and Chemotherapy 38:275-281.
8. 3. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco (abstract LB-1).
9. Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino J-M, Lane J, Black RJ, Reichelderfer PS, D'Aquila RT, Crumpacker CS (1993): Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrobial Agents and Chemotherapy 37:1095-1101.
10. Japour AJ, Welles, S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kritzkes DR (1995): Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. Journal of Infectious Diseases 171:1172-1179.
11. Kellam P, Boucher CAB, Larder BA (1992): Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proceedings of the National Academy of Sciences of the United States of America. 89:1934-1938.
12. Kellam P, Larder BA (1994): Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrobial Agents and Chemotherapy 38:23-30.
13. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC (1993): A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. Journal of Infectious Diseases 167:526-532.
14. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC (1994): Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Annals of Internal Medicine 121:263-268.
15. Lacey SF, Larder BA (1994): Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′dideoxythymidine in cell culture. Antimicrobial Agents and Chemotherapy 38:1428-1432.
16. Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, Knupp C, McLaren C, Pettinelli C, Valentine FT, Dolin R (1990): 2′-3′-dideoxysinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: A phase I trial. New England Journal of Medicine 322:1333-1340.
17. Larder BA, Kemp SD (1989): Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:1155-1158.
18. Lee LG, Connell CR, Woo SL, Cheng RD, McArdle BF, Fuller CW, Halloran ND, Wilson RK (1992): DNA sequencing with dye-labeled terminators and T7 DNA polymerase: Effect of dyes and dNTP's on incorporation of dye-terminators and probability analysis of termination fragments. Nucleic Acids Research 20:2471-2483.
19. Lin P-F, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, Revie DR, Khan NC, Federici ME, Li H, Lee A, Anderson RE, Colonno RJ (1994): Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. Journal of Infectious Diseases 170:1157-1164.
20. Mayers DL, Japoùr AJ, Arduino J-M, Hammer SM, Reichman R, Wagner KF, Chung R, Lane J, Crumpacker CS, McLeod GX, Beckett LA, Roberts CR, Winslow D, Burke D (1994): Dideoxynucleoside resistance emerges with prolonged zidouvudine monotherapy. Antimicrobial Agents and Chemotherapy 38:307-314.
21. Masquelier B, Pellegrin I, Ruffault A, Ragnaud J-M, Morlat P, Michelet C, Doignon F, Biteau N, Fleury HJA (1995): Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine. Journal of Acquired Immune Deficiency Syndromes 8:330-334.
22. McLeod GX, McGrath JM, Ladd EA, Hammer SM (1992): Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. Antimicrobial Agents and Chemotherapy 36:920-925.
23. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, Gupta P (1995): Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of Internal Medicine 122: 573-579.
24. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, Rubin M, Simberkoff MS, Hamilton JD (1996): Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. New England Journal of Medicine 334:426-431.
25. Reichman RC, Tejani N, Lambert JL, Strussenberg J, Bonnez W, Blumberg B, Epstein L, Dolin R (1993): Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddl. Antiviral Research 20:267-277.
26. Sanchez-Pescador R, Power MD, Barr PJ, Steimer KS, Stempien MM, Brown-Shimer SL, Gee WW, Renare A, Randolph A, Levy JA, Dina D, Luciw PA (1985): Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science 227:484-492.
27. Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L (1994): Rates and risk factors for adverse events associated with didanosine in the expanded access program. Journal of Infectious Diseases 19: 1076-1083.
28. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J, Boucher CAB (1995): Rapid changes in human immunodeficiency virus type-1 RNA load and appearance of dug-resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases 171:1411-1419.
29. Shepp DH, Ashraf A (1993): Effect of didanosine on human immunodeficiency virus viremia and antigenemia in patients with advanced disease: Correlation with clinical response. Journal of Infectious Diseases 167:30-35.
30. Smith MS, Koerber KL, Pagano JS (1994): Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy. Journal of Infectious Diseases 169:184-188.
31. Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, Frank I, Remick SC, Thompson M, MacArthur RD, Morey GE, Ramirez-Ronda CH, Bernstein BM, Sweet DE, Crane L, Peterson EA, Pachucki CT, Green SL, Brand J, Rios A, Dunkle LM, Cross A, Brown MJ, Ingraham P, Gugilotti R, Schindzielorz AH, Smaldone L (1994): Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. Annals of Internal Medicine 120:360-368.
32. St. Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA (1991): Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
33. Yarchoan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, Hartman N, Johns DG, Broder S (1990): Long-term toxicity/ activity profile of 2′-,3′-dideoxysinosine in AIDS or AIDS-related complex. Lancet 366:526-529.
34. Zhang D, Caliendo AM, Eron JJ, DeVore KM, Kaplan JC, Hirsch MS, D'Aquila RT (1994): Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 38:282-287.